ZERBAXA Webcast Highlights
ZERBAXA® (ceftolozane/tazobactam) Webcast Highlights
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Managing resistant Gram-Negative Infections in critically ill, ventilated patients – treatment options and new insights
This webcast was fully organised and funded by MSD and recorded in 2023.
ZERBAXA® (ceftolozane/tazobactam) is indicated for the treatment of adults with Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).1
Please refer to the Prescribing information for full details, including dosing.
Meet our speaker Dr. Sunny Kaul
Dr. Sunny Kaul is a Consultant in Respiratory and Critical Care and General Internal Medicine, at the Clinical Lead Department Respiratory Medicine, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust
1 – Early Appropriate Antibiotic Interventions
Length: 03:27 minutes
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
2 – The Bug and the Syndrome
Length: 02:43 minutes
3 – Management of Patients with Nosocomial Pneumonia
Length: 12:15 minutes
4 – Importance of Local Susceptibility and Surveillance Data: Sharing Best Practice
Length: 14:12 minutes
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
5 – Further considerations of the ASPECT-NP Data
Length: 03:51 minutes
6 – Evaluating the Cost Behind the Treatment
Length: 02:47 minutes
7 – Personalisation of Treatment
Length: 03:20 minutes
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
8 – The Impact of COVID-19 on Patient Management
Length: 02:06 minutes
Reference
- ZERBAXA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
